<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01415102</url>
  </required_header>
  <id_info>
    <org_study_id>B2031001</org_study_id>
    <nct_id>NCT01415102</nct_id>
  </id_info>
  <brief_title>A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Inhaled Doses Of PF-05212372.</brief_title>
  <official_title>A Double Blind (3rd Party Open), Randomised, Placebo-Controlled, Dose Escalation Study To Investigate The Safety, Toleration, And Pharmacokinetics Of Single Inhaled Doses Of Pf-05212372 In Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study in healthy people is to evaluate safety, toleration and time course
      of plasma concentration of single inhaled doses of PF-05212372.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma pharmacokinetics</measure>
    <time_frame>up to 72 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine pharmacokinetics</measure>
    <time_frame>up to 24 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine Pharmacodynamics</measure>
    <time_frame>up to 24 hours post dose</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Phase 1</condition>
  <condition>Single Dose</condition>
  <condition>Safety</condition>
  <condition>Toleration</condition>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be assigned to receive either PF-05212372 or placebo in each period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be assigned to receive either PF-05212372 or placebo in each period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05212372</intervention_name>
    <description>Inhaled. Dose Level 1: 50 ug</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05212372</intervention_name>
    <description>Inhaled. Dose Level 2 - Dose to be selected based upon safety/tolerability/PK at preceding dose</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05212372</intervention_name>
    <description>Inhaled. Dose Level 3 - Dose to be selected based upon safety/tolerability/PK at preceding dose</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05212372</intervention_name>
    <description>Inhaled. Dose Level 4 - Dose to be selected based upon safety/tolerability/PK at preceding dose</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inhaled</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05212372</intervention_name>
    <description>Inhaled. Dose Level 5 - Dose to be selected based upon safety/tolerability/PK at preceding dose</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05212372</intervention_name>
    <description>Inhaled. Dose Level 6 - Dose to be selected based upon safety/tolerability/PK at preceding dose</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05212372</intervention_name>
    <description>Inhaled. Dose Level 7 - Dose to be selected based upon safety/tolerability/PK at preceding dose</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inhaled</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Healthy subjects. (Healthy is defined as no clinically relevant abnormalities identified by
        a detailed medical history, full physical examination, including blood pressure and pulse
        rate measurement, 12-lead ECG and clinical laboratory tests).

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,
             seasonal allergies at time of dosing).

          -  A positive urine drug screen.

          -  Treatment with an investigational drug within the past 30 days (or local regulations)
             or 5 half-lives preceding the first dose of study medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>B-1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B2031001&amp;StudyName=A%20First%20In%20Human%20Study%20In%20Healthy%20People%20To%20Evaluate%20Safety%2C%20Toleration%20And%20Time%20Course%20Of%20Plasma%20Concentration%20Of%20Single%20Inhaled%20</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2010</study_first_submitted>
  <study_first_submitted_qc>August 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2011</study_first_posted>
  <last_update_submitted>August 12, 2011</last_update_submitted>
  <last_update_submitted_qc>August 12, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2011</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

